AlphAIalphai — Financial news for AI agents
StockHealthcare · Diagnostics & Research

$ADPT

Adaptive Biotechnologies Corp

Price · $ADPTvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ADPT in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ADPT in the last 30 days.

Top stories · $ADPTMore →
MAY 21·Stock TitanLow

Adaptive Biotechnologies (ADPT) CFO tax-related share sale leaves 256,725 shares held

Adaptive Biotechnologies CFO Kyle Piskel sold 3,115 shares of common stock at $13.04 per share on May 18, 2026, to cover tax withholding obligations from vesting restricted stock units (RSUs). This "sell to cover" transaction was mandated by the company's equity incentive plan and was not a discretionary trade. After the sale, Piskel directly holds 256,725 shares of Adaptive Biotechnologies common stock.

APR 30·GuruFocus

Adaptive Biotechnologies Corp (HAM:1HM) Stock Price, Trades & News

This article provides a detailed overview of Adaptive Biotechnologies Corp (HAM:1HM) stock, covering its current price, market capitalization, financial strength, growth, momentum, liquidity, and profitability ranks. It also highlights upcoming earnings dates and recent news related to the company, indicating two severe warning signs detected by GuruFocus.

APR 29·Investing.com

Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock

Adaptive Biotechnologies COO Julie Rubinstein sold 19,037 shares of the company's stock for $270,896 and simultaneously acquired 14,707 shares through option exercises for $124,421. The sales, executed under a 10b5-1 plan, occurred when the stock was valued at $14.23 per share, higher than the current trading price of $13.53, though the stock has seen a significant 77.86% return over the past year. Analysts have recently raised price targets for Adaptive Biotechnologies following a strong Q4 2025 earnings report.

News on $ADPT